Vaccination of Prostate Cancer Patients With Thompson-Friedenreich [TF(c)]-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Comparing TF(c)-KLH Doses

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven progressive prostate cancer after primary
therapy Radiographic changes OR PSA at least 1.0 ng/mL and rising after prostatectomy OR
PSA at least 2.0 ng/mL and rising after radiotherapy OR PSA rising 50% during intermittent
hormonal therapy No metastatic disease by radiography No active CNS or epidural tumor
Registered on MSKCC-9040

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life
expectancy: At least 6 months Hematopoietic: WBC at least 3500/mm3 Platelet count at least
100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL OR SGOT less than 3.0 times upper limit
of normal Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance at least 40
mL/min Cardiovascular: No New York Heart Association class III/IV cardiac disease
Pulmonary: No severe debilitating pulmonary disease Other: No other active malignancy
within 5 years except nonmelanomatous skin cancer No infection requiring antibiotics No
narcotic dependent pain No positive stool guaiac excluding hemorrhoids No radiation
induced proctitis No allergy to seafood

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
since prior chemotherapy and recovered No concurrent chemotherapy Endocrine therapy: See
Disease Characteristics At least 2 weeks since change in hormonal therapy (except to
maintain castrate levels of testosterone), including prednisone or dexamethasone At least
8 weeks since prior suramin and/or serum concentration of suramin must be less than 50
micrograms/mL (replacement hydrocortisone allowed) Radiotherapy: See Disease
Characteristics At least 4 weeks since prior radiotherapy and recovered No concurrent
therapy to only measurable lesion Surgery: See Disease Characteristics No concurrent
surgery